Non-Hodgkin's lymphoma with bone involvement: A single center experience with 18 patients

Basit Öğe Kaydı
dc.contributor.authorVural F.
dc.contributor.authorSoyer N.A.
dc.contributor.authorÖzen P.
dc.contributor.authorDönmez A.
dc.contributor.authorOcakçi S.
dc.contributor.authorSaydam, G..
dc.contributor.authorÇagirgan S.
dc.contributor.authorTombuloglu M.
dc.date.accessioned2019-10-26T22:39:26Z
dc.date.available2019-10-26T22:39:26Z
dc.date.issued2010
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: Non-Hodgkin's lymphoma (NHL) of bone is a rare entity. The most common histological subtype is diffuse large B cell lymphoma (DLBCL). The major presenting symptoms are soft tissue swelling, bone pain and pathological fracture. Treatment options are chemotherapy, radiotherapy, surgery, or a combination of these modalities. Materials and Methods: We retrospectively analyzed the 18 patients (11 females, 7 males) with NHL of bone who were diagnosed and treated between 1995-2005. The median age was 56.5 years. The median duration of symptoms was 4.5 months. The bone pain was the first symptom in all patients. Tru-cut biopsy was performed for diagnosis in most of the cases. Diagnosis in five patients (27.8%) required open biopsy. Results: DLBCL (77.8%) was the most common histological type among all patients. Other histological subtypes were anaplastic large cell lymphoma (11.1%), Burkitt-like lymphoma (5.6%) and marginal zone lymphoma (5.6%). According to Ann Arbor staging system, 44.4% of patients were Stage I, 11.1% were Stage II and 44.4% were Stage IV. Bone marrow involvement was determined in four patients (22.2%). All patients except one were treated with anthracycline-containing regimens and eight patients (44.4%) received rituximab combination with chemotherapy. Radiation therapy was performed as the first-line therapy in 9 (50%) patients. The median follow-up was 37 months (range, 2-124 months). Among the 17 patients who achieved complete remission, five (27.8%) relapsed. All patients were still alive. The five-year relapsefree survival was 73.5%. Conclusion: The treatment of bone lymphoma can be planned according to the stage and location of the disease. Although we had a relatively low number of patients, it could be concluded that whether or not radiation therapy is performed, rituximab in combination with systemic chemotherapy has been proven beneficial on survival.en_US
dc.identifier.endpage33en_US
dc.identifier.issn1300-7777
dc.identifier.issn1300-7777en_US
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage29en_US
dc.identifier.urihttps://hdl.handle.net/11454/19968
dc.identifier.volume27en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.relation.ispartofTurkish Journal of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBoneen_US
dc.subjectLymphomaen_US
dc.subjectNon-Hodgkin's lymphomaen_US
dc.titleNon-Hodgkin's lymphoma with bone involvement: A single center experience with 18 patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu